Amedeo Smart

Free Medical Literature Service

 

Amedeo

Andrology
  Free Subscription

Articles published in
Prostate
    April 2024
  1. ROPER C, Slade A, Caras R, Shelton T, et al
    Ejaculatory and erectile function outcomes following holmium laser enucleation of the prostate.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24697.
    >> Share

  2. ZHANG Y, Dong Y, Mei Z, Hou Y, et al
    Performance of large language models on benign prostatic hyperplasia frequently asked questions.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24699.
    >> Share

    March 2024
  3. ZHAO X, Feng R, Chen J, Jiang Q, et al
    4-Octyl itaconate alleviates experimental autoimmune prostatitis by inhibiting the NLRP3 inflammasome-induced pyroptosis through activating Nrf2/HO-1 pathway.
    Prostate. 2024;84:329-341.
    >> Share

    February 2024
  4. KAMADA S, Sakamoto S, Kinoshita R, Zhao X, et al
    Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
    Prostate. 2024 Feb 27. doi: 10.1002/pros.24679.
    >> Share

  5. SHIBAMORI K, Kyoda Y, Shindo T, Hashimoto K, et al
    Maternal diet during gestation affect prostatic tissue component in SHR/Izm offspring.
    Prostate. 2024;84:303-314.
    >> Share

    January 2024
  6. CAVANAUGH D, Urbanucci A, Mohamed NE, Tewari AK, et al
    Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS).
    Prostate. 2024 Jan 9. doi: 10.1002/pros.24656.
    >> Share

  7. WHITE JA, Kaninjing ET, Adeniji KA, Jibrin P, et al
    Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
    Prostate. 2024 Jan 8. doi: 10.1002/pros.24662.
    >> Share

  8. JIN R, Forbes CM, Miller NL, Lafin J, et al
    Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
    Prostate. 2024 Jan 3. doi: 10.1002/pros.24661.
    >> Share

    December 2023
  9. LEE KS, Yoo JW, Kim DH, Jeon S, et al
    A prospective, randomized, open-label, parallel trial comparing the efficacy of alpha-blocker or 5alpha-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyp
    Prostate. 2023 Dec 27. doi: 10.1002/pros.24663.
    >> Share

  10. SCHNEIDER AJ, Serrell EC, Grimes M, Wang S, et al
    Histologic inflammation and collagen content are not positively correlated in human BPH.
    Prostate. 2023;83:1529-1536.
    >> Share

    November 2023
  11. MARIOTTI ACH, Heidrich V, Inoue LT, Coser EM, et al
    Urinary microbiota is associated to clinicopathological features in benign prostatic hyperplasia.
    Prostate. 2023 Nov 13. doi: 10.1002/pros.24649.
    >> Share

    October 2023
  12. DI H, Wen Y
    Vasectomy and risk of prostate cancer: A Mendelian randomization study and confounder analysis.
    Prostate. 2023 Oct 31. doi: 10.1002/pros.24646.
    >> Share

  13. ZHOU H, Xu M, Pan Y, Wang S, et al
    The association between several serum micronutrients and benign prostatic hyperplasia: Results from NHANES 2003-2006.
    Prostate. 2023 Oct 29. doi: 10.1002/pros.24641.
    >> Share

  14. HATA J, Matsuoka K, Akaihata H, Meguro S, et al
    The activated complement pathway in the fibrous process of benign prostatic hyperplasia.
    Prostate. 2023 Oct 25. doi: 10.1002/pros.24639.
    >> Share

  15. ZHANG Y, Peng R, Chen Z, Zhang W, et al
    Evidence for a causal effect of major depressive disorder, anxiety on prostatitis risk: A univariate and multivariate Mendelian randomization study.
    Prostate. 2023;83:1387-1392.
    >> Share

  16. WESTHOFEN T, Bensel M, Schlenker B, Becker A, et al
    The impact of previous inguinal mesh hernioplasty on oncological and patient-reported outcomes following radical prostatectomy.
    Prostate. 2023;83:1313-1322.
    >> Share

    September 2023
  17. FUJIWARA S, Kosaka T, Nishimoto Y, Kamisawa K, et al
    Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel.
    Prostate. 2023 Sep 3. doi: 10.1002/pros.24620.
    >> Share

    July 2023
  18. LV K, Yang G, Wu Y, Xia X, et al
    The causal effect of metabolic syndrome and its components on benign prostatic hyperplasia: A univariable and multivariable Mendelian randomization study.
    Prostate. 2023 Jul 16. doi: 10.1002/pros.24598.
    >> Share

    June 2023
  19. SEVIM M, Alkis O, Kartal IG, Kazan HO, et al
    Comparison of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation in category IIIB chronic prostatitis/chronic pelvic pain syndrome: A randomized prospective trial.
    Prostate. 2023;83:751-758.
    >> Share

  20. LI Z, Lao Y, Bai Y, Li W, et al
    Re: Comparison of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation in category IIIB chronic prostatitis/chronic pelvic pain syndrome: A randomized prospective trial.
    Prostate. 2023;83:896-897.
    >> Share

  21. LEBANI BR, Barcelos ADS, Gouveia DSES, Girotti ME, et al
    The role of transurethral resection of prostate (TURP) in patients with underactive bladder: 12 months follow-up in different grades of detrusor contractility.
    Prostate. 2023;83:857-862.
    >> Share

    May 2023
  22. LEE S, Yoo KH, Kim TS, Cho HJ, et al
    Characteristics of recurrent acute urinary retention in BPH patients in the United States: Retrospective analysis of US-based insurance claims database.
    Prostate. 2023;83:722-728.
    >> Share

  23. BABAR M, Loloi J, Tang K, Singh S, et al
    Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population.
    Prostate. 2023;83:713-721.
    >> Share

    April 2023
  24. BENGTSEN MB, Heide-Jorgensen U, Borre M, Norgaard M, et al
    Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care.
    Prostate. 2023 Apr 14. doi: 10.1002/pros.24540.
    >> Share

    March 2023
  25. MIYAZAWA Y, Nakamura T, Takezawa Y, Shimizu N, et al
    A prospective study of the relationship between CRPC patient's quality of life after enzalutamide and serum testosterone levels measured via LC-MS/MS.
    Prostate. 2023 Mar 9. doi: 10.1002/pros.24514.
    >> Share

    February 2023
  26. BECK J, Rouleau M, Lemire F, Neveu B, et al
    Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
    Prostate. 2023 Feb 27. doi: 10.1002/pros.24501.
    >> Share

    November 2022
  27. NANDALUR KR, Walker D, Ye H, Al-Katib S, et al
    Impact of the bladder detrusor muscular ring on lower urinary tract symptoms due to benign prostatic hyperplasia: A quantitative MRI analysis.
    Prostate. 2022 Nov 7. doi: 10.1002/pros.24457.
    >> Share

  28. NYGARD LH, Talala K, Taari K, Tammela TLJ, et al
    Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.
    Prostate. 2022 Nov 3. doi: 10.1002/pros.24456.
    >> Share

    October 2022
  29. JIN R, Forbes C, Miller NL, Strand D, et al
    Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
    Prostate. 2022;82:1378-1388.
    >> Share

    September 2022
  30. BENGTSEN MB, Heide-Jorgensen U, Borre M, Knudsen JS, et al
    Acute urinary retention in men: 21-year trends in incidence, subsequent benign prostatic hyperplasia-related treatment and mortality: A Danish population-based cohort study.
    Prostate. 2022 Sep 20. doi: 10.1002/pros.24440.
    >> Share

  31. SEVIM M, Alkis O, Kartal IG, Coser S, et al
    Impact of COVID-19 on the progression of benign prostatic hyperplasia and aggravation of related symptoms: A prospective study.
    Prostate. 2022 Sep 8. doi: 10.1002/pros.24439.
    >> Share

  32. JIA L, Strand DW, Goueli RS, Gahan JC, et al
    PSA density is associated with BPH cellular composition.
    Prostate. 2022;82:1162-1169.
    >> Share

  33. HUA X, Zhang J, Ge S, Liu H, et al
    CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation.
    Prostate. 2022;82:1223-1236.
    >> Share

    May 2022
  34. ASKER H, Yilmaz-Oral D, Oztekin CV, Gur S, et al
    An update on the current status and future prospects of erectile dysfunction following radical prostatectomy.
    Prostate. 2022 May 17. doi: 10.1002/pros.24366.
    >> Share

  35. ZHANG M, Jin C, Kong X, Meng J, et al
    Identification of novel susceptibility factors related to CP/CPPS-like symptoms: Evidence from a multicenter case-control study.
    Prostate. 2022;82:772-782.
    >> Share

  36. MOROZOV A, Bazarkin A, Babaevskaya D, Taratkin M, et al
    A systematic review and meta-analysis of placebo effect in clinical trials on chronic prostatitis/chronic pelvic pain syndrome.
    Prostate. 2022;82:633-656.
    >> Share

    February 2022
  37. STAMIS SA, Heath EI, Lucas S, Boerner J, et al
    Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
    Prostate. 2022 Feb 8. doi: 10.1002/pros.24310.
    >> Share

  38. DROGHETTI M, Porreca A, Bianchi L, Piazza P, et al
    Long-term outcomes of Holmium laser enucleation of prostate and predictive model for symptom recurrence.
    Prostate. 2022;82:203-209.
    >> Share

    January 2022
  39. HUANG R, Liu Y, Li B, Wang R, et al
    Inhibition of human prostate smooth muscle contraction by the inhibitors of protein kinase C, GF109203X, and Go6983.
    Prostate. 2022;82:59-77.
    >> Share

  40. KIM SW, Lee J, Oh S, Son H, et al
    Restoration of erectile function by a combination of antiapoptosis by JNK inhibitor and preservation of smooth muscle or endothelium by hepatocyte growth factor in a rat model of cavernous nerve injury.
    Prostate. 2022;82:49-58.
    >> Share

    December 2021
  41. IGARASHI T, Tyagi P, Mizoguchi S, Saito T, et al
    Therapeutic effects of nerve growth factor-targeting therapy on bladder overactivity in rats with prostatic inflammation.
    Prostate. 2021;81:1303-1309.
    >> Share

    November 2021
  42. CHEN J, Zhang LG, Du HX, Zhan CS, et al
    Melatonin attenuates prostatic inflammation and pelvic pain via Sirt1-dependent inhibition of the NLRP3 inflammasome in an EAP mouse model.
    Prostate. 2021;81:1179-1190.
    >> Share

    October 2021
  43. CHEN J, Meng J, Jin C, Mo F, et al
    4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy for chronic prostatitis.
    Prostate. 2021;81:1078-1090.
    >> Share

    September 2021
  44. LIU D, Liu J, Li Y, Liu H, et al
    Upregulated bone morphogenetic protein 5 enhances proliferation and epithelial-mesenchymal transition process in benign prostatic hyperplasia via BMP/Smad signaling pathway.
    Prostate. 2021 Sep 23. doi: 10.1002/pros.24241.
    >> Share

  45. CASTRO NFDC, Jubilato FC, Guerra LHA, Santos FCAD, et al
    Therapeutic effects of beta-caryophyllene on proliferative disorders and inflammation of the gerbil prostate.
    Prostate. 2021;81:812-824.
    >> Share

  46. INES M, Babar M, Singh S, Iqbal N, et al
    Real-world evidence with The Rezum System: A retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes.
    Prostate. 2021;81:956-970.
    >> Share

    August 2021
  47. LIAO G, Lee PMY, Zhao S, Ho WM, et al
    Joint effect between bisphenol A and alcohol consumption on benign prostatic hyperplasia: A case-control study in Hong Kong Chinese males.
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24217.
    >> Share

  48. LI Y, Wang Q, Li J, Shi B, et al
    SIRT3 affects mitochondrial metabolic reprogramming via the AMPK-PGC-1alpha axis in the development of benign prostatic hyperplasia.
    Prostate. 2021 Aug 19. doi: 10.1002/pros.24208.
    >> Share

    July 2021
  49. JIN R, Strand DW, Forbes CM, Case T, et al
    The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Prostate. 2021 Jul 20. doi: 10.1002/pros.24190.
    >> Share

  50. BASSILY D, Wong V, Phillips JL, Fraiman M, et al
    Rezum for retention-retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia.
    Prostate. 2021 Jul 20. doi: 10.1002/pros.24201.
    >> Share

    June 2021
  51. MYKONIATIS I, Pyrgidis N, Kalyvianakis D, Zilotis F, et al
    Comparing two different low-intensity shockwave therapy frequency protocols for nonbacterial chronic prostatitis/chronic pelvic pain syndrome: A two-arm, parallel-group randomized controlled trial.
    Prostate. 2021;81:499-507.
    >> Share

  52. QIAN Q, He W, Liu D, Yin J, et al
    M2a macrophage can rescue proliferation and gene expression of benign prostate hyperplasia epithelial and stroma cells from insulin-like growth factor 1 knockdown.
    Prostate. 2021;81:530-542.
    >> Share

    April 2021
  53. QIAN S, Zhang S, Xia W, Xu D, et al
    Correlation of prostatic morphological parameters and clinical progression in aging Chinese men with benign prostatic hyperplasia: Results from a cross-sectional study.
    Prostate. 2021 Apr 16. doi: 10.1002/pros.24128.
    >> Share

    March 2021
  54. AYDOGDU O, Gocun PU, Aronsson P, Carlsson T, et al
    Prostate-to-bladder cross-sensitization in a model of zymosan-induced chronic pelvic pain syndrome in rats.
    Prostate. 2021;81:252-260.
    >> Share

    January 2021
  55. LIU Y, Zhang Y, Zhang M, Meng J, et al
    Activated autophagy restored the impaired frequency and function of regulatory T cells in chronic prostatitis.
    Prostate. 2021;81:29-40.
    >> Share

    December 2020
  56. ZHANG LG, Yu ZQ, Yang C, Chen J, et al
    Effect of Eriocalyxin B on prostatic inflammation and pelvic pain in a mouse model of experimental autoimmune prostatitis.
    Prostate. 2020;80:1394-1404.
    >> Share

  57. MIZOGUCHI S, Mori K, Shin T, Wang Z, et al
    Effects of dutasteride in a rat model of chemically induced prostatic inflammation-Potential role of estrogen receptor beta.
    Prostate. 2020;80:1413-1420.
    >> Share

    November 2020
  58. JAIN S, Samal AG, Das B, Pradhan B, et al
    Escherichia coli, a common constituent of benign prostate hyperplasia-associated microbiota induces inflammation and DNA damage in prostate epithelial cells.
    Prostate. 2020;80:1341-1352.
    >> Share

  59. GAT Y, Joshua S, Vuk-Pavlovic S, Goren M, et al
    Paying the price for standing tall: Fluid mechanics of prostate pathology.
    Prostate. 2020;80:1297-1303.
    >> Share

    October 2020
  60. WANG K, Pascal LE, Li F, Chen W, et al
    Tight junction protein claudin-1 is downregulated by TGF-beta1 via MEK signaling in benign prostatic epithelial cells.
    Prostate. 2020;80:1203-1215.
    >> Share

  61. CHEN W, Pascal LE, Wang K, Dhir R, et al
    Differential impact of paired patient-derived BPH and normal adjacent stromal cells on benign prostatic epithelial cell growth in 3D culture.
    Prostate. 2020;80:1177-1187.
    >> Share

    September 2020
  62. EPSTEIN DJ, Thompson LDR, Saleem A, Kao CS, et al
    Fungal prostatitis due to endemic mycoses and Cryptococcus: A multicenter case series.
    Prostate. 2020;80:1006-1011.
    >> Share

  63. PENG X, Guo H, Chen J, Wang J, et al
    The effect of pirfenidone on rat chronic prostatitis/chronic pelvic pain syndrome and its mechanisms.
    Prostate. 2020;80:917-925.
    >> Share

  64. SMITH DK, Hasanali SL, Wang J, Kallifatidis G, et al
    Promotion of epithelial hyperplasia by interleukin-8-CXCR axis in human prostate.
    Prostate. 2020;80:938-949.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016